Home Tags American Society of Hematology

Tag: American Society of Hematology

IMGN632, a Novel CD123-Targeting Antibody-drug Conjugate, Demonstrates Activity in Acute Myeloid...

Preclinical data on IMGN632, a novel CD123-targeting antibody-drug conjugate being developed by ImmunoGen, presented at the 58th American Society of Hematology (ASH) Annual Meeting...

ASH 2016: Informative and Clinical Useful

Each year, ahead of key annual medical society meetings we ask the same question: What to expect during the upcoming meeting.  Are we going...

Blinatumomab Shows Positive Outcomes in Acute Lymphoblastic Leukemia

Data presented during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida shows that Amgen’s blinatumomab (Blincyto®)...

Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament

Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in Orlando, Florida from December 5–8,...

IMGN779 Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML...

CD33 is broadly expressed on leukemic blasts of patients with acute myeloid leukemia.  Although nearly 80% of patients show a high initial response rates to chemotherapy, many...

Vadastuximab Talirine Demonstrates Encouraging Anti-leukemic Activity in Acute Myeloid Leukemia

Several presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating vadastuximab...

Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...

Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy.  Oral...

Denintuzumab Mafodotin: Testing Novel Regimens for Frontline and Relapsed DLBCL

Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...

Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...

Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...

Four-Year Survival Data from Brentuximab Vedotin Trial in Relapsed or Refractory...

Four-year overall survival (OS) data from the brentuximab vedotin (Adcetris®; Seattle Genetics) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell...

X